Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,646,000.00
Day range
₩1,605,000.00 - ₩1,655,000.00
Year range
₩908,000.00 - ₩1,841,000.00
Market cap
74.39T KRW
Avg Volume
67.10K
P/E ratio
46.61
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 1.66T | 39.86% |
Operating expense | 245.96B | 21.59% |
Net income | 574.46B | 117.21% |
Net profit margin | 34.60 | 55.30% |
Earnings per share | 8.07K | 41.26% |
EBITDA | 907.77B | 83.24% |
Effective tax rate | 25.10% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.96T | 98.36% |
Total assets | 18.34T | 14.42% |
Total liabilities | 6.16T | 13.30% |
Total equity | 12.18T | — |
Shares outstanding | 46.29M | — |
Price to book | 6.26 | — |
Return on assets | 10.09% | — |
Return on capital | 13.79% | — |
Cash Flow
Net change in cash
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 574.46B | 117.21% |
Cash from operations | 619.30B | -16.36% |
Cash from investing | -213.70B | 51.11% |
Cash from financing | -202.25B | 71.65% |
Net change in cash | 212.65B | 149.08% |
Free cash flow | 333.74B | 2,853.05% |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,770
